Search

Uncertainties and opportunities in ophthalmology training after the COVID-19 pandemic

Alexander Jones asks what impact the current pandemic will have on ophthalmology trainees. In my work as a Clinical Teaching Fellow, I have to admit that chaos is uncommon. Neither the anxious excitement of rushing to help an unwell patient...

Ophthalmology Foundation: a promising new beginning

The world’s leaders in ophthalmology have created the new Ophthalmology Foundation, to make prevention of blindness and maintenance of high quality vision accessible to people of all nations. Board of Directors President David EI Pyott explains their vision for the...

Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience

Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...

Artificial intelligence and oculomics: Improving global health

The application of artificial intelligence (AI), and in particular deep learning, to high-resolution ocular imaging has led to many new discoveries, enabling the prediction of multiple different systemic diseases from ocular biomarkers. This emerging field is known as ‘oculomics’ [1]....

Reflections on a twelve-year partnership: The Makassar-Dundee LINK

In the first article of a two-part series (see Part 2 here), the authors provide an overview of this hugely successful partnership and how they overcame the challenges of COVID-19. What began in 2008 as a connection between equals, has...

See sweet to C-suite: Peter Holland

See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...